Non-small cell lung carcinoma
HCMHUTCHMED (China) LimitedCatalyst overview
Research summary
This catalyst tracks a Phase 3 update for ORPATHYS (Savolitinib) + TAGRISSO in Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
SAFFRON, SAVANNAH trials. 1/2/25- NDA accepted in China. 6/2/25- Presented SAVANNAH results at ASCO'25. 03/05/26:- SAFFRON enrollment complete; topline results expected H2 2026. 05/22/26:- Osimertinib plus savolitinib Phase 2 study in resistant NSCLC will be published for ASCO 2026. 07/30/26:- SAFFRON and SANOVO topline results remain expected in H2 2026. 08/17/26:- SAFFRON Ph3 high-level PFS and OS results were positive. Full results to be presented at a medical meeting.
Verification
Confirm timing and program details against the company announcement or filing.